Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Phase 1 Dose-Escalation Study of the Oral Epichaperome Inhibitor, Zelavespib (ZEL) in Combination with Ruxolitinib (RUX), in Patients with Relapsed Myelofibrosis: Results of the Dose Escalation Stage

Naveen Pemmaraju, Krishna Gundabolu, Jack Snyder, Michael H Silverman, Geraldine Bardelli, Srdan Verstovsek, Gary J. Schiller

Blood (2022) 140 (Supplement 1): 6821–6822.

https://doi.org/10.1182/blood-2022-169852

Published: 2022

Journal Articles

Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2 V617F Allele Burden

Animesh Pardanani, MBBS, PhD, Jason R Gotlib, MD, MS, Catriona Jamieson, MD, PhD, Jorge E. Cortes, MD, Moshe Talpaz, MD, Richard M Stone, M.D., Michael H Silverman, MD, FACP, Jolene Shorr, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD

Blood (2010) 116 (21): 459.

https://doi.org/10.1182/blood.V116.21.459.459

Published: 2010

Journal Articles

A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2 V617F Allele Burden.

Animesh D. Pardanani, MBBS, PhD, Jason R Gotlib, MD, MS, Catriona Jamieson, MD, PhD, Jorge Cortes, MD, Moshe Talpaz, MD, Richard Stone, MD, Michael H Silverman, MD, FACP, Jolene Shorr, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 755.

https://doi.org/10.1182/blood.V114.22.755.755

Published: 2009

Journal Articles

A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis

Animesh D. Pardanani, MBBS, PhD, Jason Gotlib, MD, MS, Catriona Jamieson, MD, PhD, Jorge Cortes, MD, Moshe Talpaz, MD, Richard M. Stone, MD, Michael H Silverman, MD, FACP, Jolene Shorr, D. Gary Gilliland, Ayalew Tefferi, MD

Blood (2008) 112 (11): 97.

https://doi.org/10.1182/blood.V112.11.97.97

Published: 2008

Journal Articles

Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor.

Jorge Cortes, James M. Foran, Marcel P. Devetten, Francis J. Giles, Joyce James, Patrick P. Zarrinkar, Michael H. Silverman, Kerry A. Kelly, Norman M. Padre, Shripad Bhagwat, Wendell Wierenga

Blood (2007) 110 (11): 1597.

https://doi.org/10.1182/blood.V110.11.1597.1597

Published: 2007

NARROW

A Phase 1 Dose-Escalation Study of the Oral Epichaperome Inhibitor, Zelavespib (ZEL) in Combination with Ruxolitinib (RUX), in Patients with Relapsed Myelofibrosis: Results of the Dose Escalation Stage

Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2 V617F Allele Burden

A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2 V617F Allele Burden.

A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis

Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

A Phase 1 Dose-Escalation Study of the Oral Epichaperome Inhibitor, Zelavespib (ZEL) in Combination with Ruxolitinib (RUX), in Patients with Relapsed Myelofibrosis: Results of the Dose Escalation Stage

Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2 V617F Allele Burden

A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2 V617F Allele Burden.

A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis

Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only